title: Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
abstract: The anatomic response to intravitreal bevacizumab injection in three patients with aggressive, posterior retinopathy of prematurity is described. In all cases, the worse eye was treated with a single intravitreal injection of 0.75 mg of bevacizumab as monotherapy or complementary to laser therapy. In 24 hours, all injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment. Follow-up of up to 10 months
authors.affiliation: Pediatric Retina Department, Ophthalmology Service, Hospital Fernando Fonseca, Lisbon, Portugal.
authors.forename: António
authors.initials: A
authors.lastname: Travassos
authors.forename: Susana
authors.initials: S
authors.lastname: Teixeira
authors.forename: Pinto
authors.initials: P
authors.lastname: Ferreira
authors.forename: Isaura
authors.initials: I
authors.lastname: Regadas
authors.forename: Ana Sofia
authors.initials: AS
authors.lastname: Travassos
authors.forename: Florindo Esteves
authors.initials: FE
authors.lastname: Esperancinha
authors.forename: Isabel
authors.initials: I
authors.lastname: Prieto
authors.forename: Grapa
authors.initials: G
authors.lastname: Pires
authors.forename: Robert
authors.initials: R
authors.lastname: van Velze
authors.forename: A
authors.initials: A
authors.lastname: Valido
authors.forename: Maria do Céu
authors.initials: Mdo C
authors.lastname: Machado
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007267:Injections; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab